Other therapeutic vaccines proposed as adjunctive therapies are MIP (Mycobacterium indicus pranii, phase III), VPM1002 (recombinant BCG vaccine, phase III), H56:IC31 (phase I), ID93:GLA-SE (phase I), and TB-FLU-04L (phase IIa) (Li et al., 2017), but their efficacy for drug-resistant TB treatment has yet been tested (Parida et al., 2015). This evidence concerns the gene MIP and tuberculosis.